TetraLogic Pharmaceuticals Corp (TLOG)

[TuesdaySmall]

Dec. 18, 2019 /PRNewswire/ -- Medivir AB Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Squamous Cell Carcinoma

STOCKHOLM, Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC). This clinical study is conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete.

https://www.prnewswire.com/news-releases/investigator-initiated-phase-ii-clinical-study-of-remetinostat-started-in-patients-with-squamous-cell-carcinoma-300976709.html